54,770 TG Therapeutics, Inc. $TGTX Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC grew its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 6.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 874,023 shares of the biopharmaceutical company’s stock after acquiring an additional 54,770 shares during the quarter. Voya Investment Management LLC owned 0.57% of TG Therapeutics worth $48,753,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of TGTX. Bogart Wealth LLC bought a new position in shares of TG Therapeutics during the 3rd quarter worth about $56,000. Public Sector Pension Investment Board lifted its stake in shares of TG Therapeutics by 115.0% in the third quarter. Public Sector Pension Investment Board now owns 973,454 shares of the biopharmaceutical company’s stock valued at $52,635,000 after buying an additional 520,637 shares during the period. Edgestream Partners L.P. bought a new stake in shares of TG Therapeutics in the third quarter valued at about $4,153,000. Morse Asset Management Inc bought a new stake in shares of TG Therapeutics in the third quarter valued at about $29,000. Finally, Bessemer Group Inc. grew its position in TG Therapeutics by 119.3% during the third quarter. Bessemer Group Inc. now owns 290,660 shares of the biopharmaceutical company’s stock worth $16,213,000 after buying an additional 158,105 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the sale, the director directly owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.87% of the stock is currently owned by corporate insiders.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $64.88 on Friday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.75 and a current ratio of 4.50. The company has a 50-day moving average of $57.39 and a 200-day moving average of $46.02. TG Therapeutics, Inc. has a 52 week low of $26.76 and a 52 week high of $68.03. The company has a market capitalization of $9.81 billion, a price-to-earnings ratio of 98.30, a PEG ratio of 5.21 and a beta of 1.89.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). TG Therapeutics had a net margin of 11.81% and a return on equity of 18.82%. The business had revenue of $259.94 million during the quarter, compared to the consensus estimate of $245.47 million. During the same period in the previous year, the firm earned $2.43 EPS. The business’s revenue was up 60.8% compared to the same quarter last year. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 1.10 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday, September 1st. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Zacks Research raised TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. B. Riley Financial lifted their price objective on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Finally, Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $63.00.

Check Out Our Latest Research Report on TGTX

TG Therapeutics Profile

(Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Featured Stories

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.